Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Authors :: Richardson, Paul G. Schjesvold, Fredrik Weisel, Katja and Moreau, Philippe Anderson, Jr., Larry D. White, Darrell and Rodriguez-Otero, Paula Sonneveld, Pieter Engelhardt, Monika and Jenner, Matthew Corso, Alessandro Duerig, Jan Pavic, Michel and Salomo, Morten Beksac, Meral Oriol, Albert Lindsay, Jindriska Liberati, Anna Marina Galli, Monica Robak, Pawel and Larocca, Alessandra Yagci, Munci Vural, Filiz Kanate, Abraham S. Jiang, Ruiyun Grote, Lara Peluso, Teresa and Dimopoulos, Meletios
Publication Year :: 2022
Abstract: Objective We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. Methods OPTIMISMM was a phase 3, multicenter, open-label, randomized study (NCT01734928; N = 559). The primary endpoint was progression-free survival (PFS). Results Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged 65 years (median, 17.6 vs 9.9 months; P = .0369). Median PFS in patients with renal impairment (RI; creatinine clearance

Tools